Previous 10 | Next 10 |
Inflation is here; and that means these groups ought to be on your radar. The best stocks within every sector now. Over 20 new stocks join our 'best stocks' list this week. For further details see: The Stocks To Focus On Today
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Summer Solstice - Best Ideas fro...
Market leadership by sector and market cap. Sectors remain tilted toward mid-cycle ideas. However, stock-specific ideas are available in every basket. For further details see: The Top Stocks You Can Buy Now
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to prese...
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retin...
Alimera Sciences Inc. (ALIM) Q1 2021 Earnings Conference Call April 29, 2021 09:00 AM ET Company Participants Scott Gordon - Core IR Rick Eiswirth - President and Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Yi Che...
Image source: The Motley Fool. Alimera Sciences Inc (NASDAQ: ALIM) Q1 2021 Earnings Call Apr 29, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: Alimera Sciences Inc (ALIM) Q1 2021 Earnings Call Transcript
Alimera Sciences (ALIM): Q1 GAAP EPS of -$0.63 misses by $0.09.Revenue of $11.21M (-22.9% Y/Y) misses by $0.19M.Press Release For further details see: Alimera Sciences EPS misses by $0.09, misses on revenue
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial ...
ATLANTA, April 22, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it wil...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...
2024-06-25 07:00:05 ET Yi Chen from H.C. Wainwright issued a price target of $6.00 for ALIM on 2024-06-25 06:08:00. The adjusted price target was set to $6.00. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $7.25 with...